Weight Loss Sibutramine Raw Materials Sibutramine CAS Number: 106650-56-0 Weight Loss Burning Fat Sibutramine
1. Product title: Dextromethorphan
Sibutramine is no longer available in the United States because some people who take it are at risk of serious cardiovascular problems.
Sibutramine is used to manage obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a calorie-reducing diet. Sibutramine is recommended for obese patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors (eg, diabetes, dyslipidemia, hypertension control).
Sibutramine helps lose weight by changing neurotransmitters in the brain. Neurotransmitters are chemicals produced and released by nerves to communicate with other nerves. The released neurotransmitters may attach to other nerves, or they may be absorbed again by the nerve that released them. This process is called reuptake. Sibutramine blocks the reuptake of the neurotransmitters dopamine, norepinephrine and serotonin. Blocking the reuptake of neurotransmitter will change the balance of neurotransmitter in nerve cells, thereby affecting nerve function and interaction.
Patients taking sibutramine may lose 5-10% of their baseline body weight. In addition, sibutramine-assisted weight loss is accompanied by an improvement in blood lipids (such as cholesterol). Sibutramine was approved by the FDA in 1997.
Sibutramine must be converted to its active form in the liver. Ketoconazole (Nizoral), cimetidine (Tagamet) and erythromycin (Erytab, Eryc, Ilosone) inhibit this conversion, and the use of these drugs can lead to a decrease in the conversion rate and effectiveness of sibutramine. Several other drugs may have similar effects. These other drugs include clarithromycin (Biaxin), danazol (danacrine), diltiazem (Cardizem, Tiazac, Dilacor), fluconazole (Diflucan), fluoxetine (Prozac), and itraconazole (Franol), Propoxyphene (Darvon), Trilindomycin (Tao) and Verapamil (Verelan, Covera, Calan), Isopristin).
In patients receiving a class of drugs called selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertra Lin (Zoloft)-At the same time as monoamine oxidase inhibitor drugs (MAO inhibitors), severe reactions have been reported (serotonin syndrome). Serotonin syndrome may include one or more of the following: agitation, anxiety, dizziness, consciousness Fuzziness, excessive sweating, disorientation, joint pain, vomiting, hyperexcitability, fever, loss of coordination, loss of consciousness, tremor, increased heart rate, tremor and weakness. As mentioned earlier, sibutramine, like SSRIs, blocks The reuptake of serotonin may also lead to serotonin syndrome. Therefore, sibutramine should not be used together with MAO inhibitors, and there should be at least 2 weeks between stopping MAO inhibitors and starting sibutramine. Similarly, after stopping sibutramine and starting MAO inhibitors, there should be at least 2 weeks interval. It has been reported that serotonin syndrome is also used with drugs used for migraine with SSRIs, such as sumatriptan (mitril), zolmitriptan (zomigra), and dihydroergotamine (DHE), and Dextromethorphan (found in many cough medicines, such as robstatin-DM), pethidine (Demerol), pentazosin (Talwin) and fentanyl (Duragesic), or lithium (Escalis ). Therefore, these drugs should not be used with sibutramine